American Journal of Hematology | 2019
A multi‐institutional comparison of younger and older adults with sickle cell disease
Abstract
1. Stettler N, McKiernan CM, Melin CQ, Adejoro OO, Walczak NB. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015;313:1671-1672. 2. Tayo BO, Akingbola TS, Saraf SL, et al. Fixed low-dose hydroxyurea for the treatment of adults with sickle cell anemia in Nigeria. Am J Hematol. 2018;93:E193-E196. 3. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive switching agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75:300-326. 4. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322. 5. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358:1362-1369. 6. Fitzhugh CD, Hsieh MM, Allen D, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One. 2015;10: e0141706. 7. McGann PT, Hernandez AG, Ware RE. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood. 2017;129:155-161. 8. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3:255-260. 9. Ward J, Lewis N, Tsitsikas DA. Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea. BMJ Open Qual. 2018;7:e000218. 10. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555-2565. 11. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89: 1078-1088. 12. Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin. 2012;36:409-420. 13. Sethy S, Panda T, Jena RK. Beneficial effect of low fixed dose of hydroxyurea in vaso-occlusive crisis and transfusion requirements in adult HbSS patients: a prospective study in a tertiary care center. Indian J Hematol Blood Transfus. 2018;34:294-298. 14. Jain DL, Apte M, Colah R, et al. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatr. 2013;50:929-933. 15. Sharef SW, Al-Hajri M, Beshlawi I, et al. Optimizing hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Eur J Haematol. 2013;90:519-524. Received: 11 January 2019 Accepted: 16 January 2019